Revvity (RVTY) Q2 FY26 earnings call

Revvity delivered a strong second quarter, driven by robust Diagnostics performance and emerging AI-driven demand in Life Sciences, leading to a raised full-year outlook. The company is strategically investing in high-growth areas like high-content screening and software, while managing its portfolio through the divestiture of its China immunodiagnostics business. Management is optimistic about continued market improvement and the company's positioning in the evolving preclinical R&D landscape.